Compare
Ardelyx, Inc. vs Arrowhead Pharmaceuticals, Inc. vs Zai Lab Ltd vs MannKind Corp
| Latest fiscal year | Ardelyx, Inc. ARDX | Arrowhead Pharmaceuticals, Inc. ARWR | Zai Lab Ltd ZLAB | MannKind Corp MNKD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $407.32M | $450.82M | $457.18M | $348.97M |
| Revenue growth (YoY) | +22.1% | -45.6% | +15.0% | +22.2% |
| Gross margin | 90.3% (computed) | n/a | 58.3% (computed) | 92.3% (computed) |
| Operating margin | -10.1% | -156.9% | -50.2% | 11.1% |
| Net margin | -15.1% | -159.1% | -38.4% | 1.7% |
| Net income | -$61.60M | -$717.13M | -$175.54M | $5.86M |
| EPS (Diluted) | -$0.26 | -$5.11 | -$0.16 | $0.02 |
| Operating cash flow | -$42.48M | -$271.95M | -$150.79M | $18.25M |
| Free cash flow | -$43.98M | -$283.94M | -$158.89M | $13.69M |
| Cash & equivalents | $68.00M | n/a | $679.57M | $74.88M |
| Total assets | $501.60M | $1.74B | $1.17B | $792.18M |
| Total liabilities | $334.65M | n/a | $456.88M | $843.20M |
| Shareholders' equity | $166.95M | $50.50M | $715.50M | -$51.02M |
| Return on year-end equity | -36.9% | n/m | -24.5% | n/a |
| Shares outstanding | 244.35M | 141.29M | 1.11B | 307.83M |
Revenue, most recent five fiscal years
| Fiscal year | Ardelyx, Inc. | Arrowhead Pharmaceuticals, Inc. | Zai Lab Ltd | MannKind Corp |
|---|---|---|---|---|
| Latest | $407.32M Ended 2025-12-31 | $450.82M Ended 2026-09-30 | $457.18M Ended 2025-12-31 | $348.97M Ended 2025-12-31 |
| 1 year earlier | $333.62M Ended 2024-12-31 | $829.45M Ended 2025-09-30 | $397.61M Ended 2024-12-31 | $285.50M Ended 2024-12-31 |
| 2 years earlier | $124.46M Ended 2023-12-31 | $3.55M Ended 2024-09-30 | $266.72M Ended 2023-12-31 | $198.96M Ended 2023-12-31 |
| 3 years earlier | $52.16M Ended 2022-12-31 | $240.74M Ended 2023-09-30 | $212.67M Ended 2022-12-31 | $99.77M Ended 2022-12-31 |
| 4 years earlier | $10.10M Ended 2021-12-31 | $243.23M Ended 2022-09-30 | $144.10M Ended 2021-12-31 | $75.44M Ended 2021-12-31 |